Design, synthesis, and antiviral evaluation of 2-deoxy-D-ribosides of substituted benzimidazoles as potential agents for human cytomegalovirus infections
Rm. Zou et al., Design, synthesis, and antiviral evaluation of 2-deoxy-D-ribosides of substituted benzimidazoles as potential agents for human cytomegalovirus infections, NUCLEOS NUC, 19(1-2), 2000, pp. 125-153
Stereoselective glycosylation of 2,5,6-trichlorobenzimidazole (1b), 2-bromo
-5,6-dichlorobenzimidazole (Ic), 5,6-dichlorobenzimidazole (Id), 5,6-dichlo
robenzimidazole-2-thione (1e), 5,6-dichloro-2-(methylthio)benzimidazole (1f
), 2-(benzylthio)-5,6-dichlorobenzimidazole (1g), and 2-chloro-5,6-dimethyl
benzimidazole (Ih) with 2-deoxy-3,5-di-O-p-toluoyl-alpha-D-erythro-pentofur
anosyl chloride was achieved to give the desired beta nucleosides 2b-h. Sub
sequent deprotection afforded the corresponding free beta-D-2-deoxyriboside
s 3b-h. The 2-methoxy derivative 3i was synthesized by the treatment of 2b
with methanolic sodium methoxide. Displacement of the 2-chloro group of 2b
with lithium azide followed by a removal of the protective groups gave the
2-azido-5,6-dichlorobenzimidazole derivative (5). The 2-amino derivative (6
) was obtained by hydrogenolysis of 5 over Raney nickel. 5,6-Dichloro-2-iso
propylamino-1- (2-deoxy-beta-D-erythro-pentofuranosyl)benzimidazole (10) wa
s prepared using 2'-deoxyuridine (7), N-deoxyribofuranosyl transferase and
Id followed by functionalization of the C2 position. Antiviral evaluation o
f target compounds established that compounds 3b and 3c were active against
human cytomegalovirus (HCMV) at non-cytotoxic concentrations. The activity
of these 2-deoxy ribosides, however, was less than the activity of the par
ent riboside, 2,5,6-trichloro-1-beta-D-ribofuranosylbenzimidazole (TCRB). C
ompared to TCRB, 3b and 3c were somewhat more cytotoxic and active against
herpes simplex virus type 1. Compounds 3d-i with other substituents in the
2-position were inactive against both viruses and non-cytotoxic. In contras
t, compounds with amine substituents in the 2-position (5, 6, 10) were acti
ve against HCMV albeit less so than TCRB. These results establish that 2-de
oxy-D-ribosyl benzimidazoles are less active against the DNA virus HCMV tha
n are the corresponding D-ribosides.